NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction (PreSERVE-AMI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01495364
Recruitment Status : Completed
First Posted : December 20, 2011
Last Update Posted : April 28, 2016
Information provided by (Responsible Party):
Caladrius Biosciences, Inc.

December 9, 2011
December 20, 2011
April 28, 2016
December 2011
June 2014   (Final data collection date for primary outcome measure)
To determine safety and efficacy of intracoronary infusion of NBS10. [ Time Frame: primary outcome measured at 6 months ]
The primary endpoint includes the occurrence of AE's, SAE's and Major Adverse Cardiac Events (MACE) and the assessment of myocardial perfusion measured by quantitative gated SPECT MPI specifically looking at resting total severity score.
To determine safety and the effect of intracoronary infusion of AMR-001 on myocardial perfusion (RTSS), measured by gated SPECT MPI at baseline and six months in subjects post-STEMI [ Time Frame: primary outcome measured at 6 months ]
primary endpoint includes safety of bone marrow procurement (measured by adverse events) and AMR-001 cell infusion (including incidence of re-stenosis and stent thrombosis in addition to other adverse events)as well as efficacy measured by quantitative by gated SPECT MPI specifically looking at resting total severity score)
Complete list of historical versions of study NCT01495364 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction
A Prospective Randomized Double Blind Placebo Controlled Phase II Trial of Intra-coronary Infusion of AMR-001, a Bone Marrow Derived Autologous CD34+ Selected Cell Product, in Patients With Acute Myocardial Infarction.
This study will assess the safety and efficacy of intracoronary artery administered autologous bone marrow derived stem cells in subjects post ST segment elevation myocardial infarction (STEMI). This will be assessed by evaluating and comparing the autologous stem cell treatment group to the control group in terms of the occurrence of AE's, SAE's and Major Adverse Cardiac Events (MACE), by the change in myocardial perfusion (RTSS) measured quantitatively by gated single photon emission computed tomography myocardial perfusion imaging (gated SPECT MPI), and other secondary endpoints such as LVEF measured by cardiac MRI in addition to other endpoints.
Efficacy endpoint is at 6 months. Clinical endpoints and safety will be measured through 36 months.
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
ST Segment Elevation Myocardial Infarction
  • Biological: NBS10
    dosage = 10 or more million CD34+ cells via intracoronary infusion
    Other Name: AMR-001
  • Other: placebo
    matching placebo
  • Experimental: NBS10
    active treatment - CD34+ cells
    Intervention: Biological: NBS10
  • Placebo Comparator: placebo
    matching placebo
    Intervention: Other: placebo
Quyyumi AA, Vasquez A, Kereiakes DJ, Klapholz M, Schaer GL, Abdel-Latif A, Frohwein S, Henry TD, Schatz RA, Dib N, Toma C, Davidson CJ, Barsness GW, Shavelle DM, Cohen M, Poole J, Moss T, Hyde P, Kanakaraj AM, Druker V, Chung A, Junge C, Preti RA, Smith RL, Mazzo DJ, Pecora A, Losordo DW. PreSERVE-AMI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Intracoronary Administration of Autologous CD34+ Cells in Patients With Left Ventricular Dysfunction Post STEMI. Circ Res. 2017 Jan 20;120(2):324-331. doi: 10.1161/CIRCRESAHA.115.308165. Epub 2016 Nov 7.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
April 2016
June 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Age 18 years or older.
  2. Acute ST elevation myocardial infarction meeting ACC/AHA criteria, with symptoms of chest pain within 3 days of admission. Criteria include (ST elevation > 1mm in limb leads or 2 mm in two or more precordial leads, and increased levels of troponin, CPK MB or both).

    Chest pain syndrome can extend to more than 3 days prior to admission if its course is consistent with transient/intermittent ischemia rather than symptoms that are continuous suggesting ongoing infarction extending beyond 3 days.

  3. Successful stent placement and reperfusion within 3 days of chest pain onset and with TIMI Flow score of 2 or 3 and infarct related artery (IRA) with <20% stenosis after revascularization.
  4. Wall motion abnormality associated with the target lesion
  5. NYHA heart failure class I, II or III.
  6. Study entry LVEF <48% determined by CMR no sooner than 96 hours from stent placement.
  7. Able to provide informed written consent and willing to participate in all required study follow-up assessments.
  8. Subjects must have an INR ≤ 2.0 within 2 days of the bone marrow collection.
  9. Subjects must have a Hgb ≥ 10 grams/dL, WBC ≥ 3500 cells/mm3, a platelet count ≥ 100,000 cells/mm3, serum creatinine ≤ 2.5, and total bilirubin ≤ 2.0 within 7 days of the bone marrow collection or by end of screening phase.
  10. Expected survival of at least one year.
  11. Females of child bearing potential agree to use birth control (barrier method accepted) for one month post bone marrow harvest.


  1. Continuous/ongoing chest pain - unremitting and unresponsive to nitroglycerin or rest - persisting 4 or more days before stent placement. If the chest pain syndrome is transient and/or intermittent - even if it began more than 3 days prior to admission - the patient is not excluded.
  2. Subjects in cardiogenic shock (systolic pressure < 80mm/Hg, on vasopressors, or intra-aortic counterpulsation) at the time of consenting. Subjects who recover from cardiogenic shock by the time of consenting are eligible.
  3. Subjects unable to receive antiplatelet agents (e.g. aspirin, clopidogrel, ticlopidine, prasugrel, etc).
  4. Subjects receiving warfarin who have an INR >2 or with major bleeding requiring active transfusion support.
  5. Subjects who require continuous anticoagulation during the time when the bone marrow harvest is scheduled, as heparin must be discontinued for 4 hours prior to and 24 hours after bone marrow harvest procedure. (See Appendix VII.)
  6. Subjects with severe cardiac valvular disease expected to undergo surgery within 1 year.
  7. Subjects with known severe immunodeficiency states (AIDS).
  8. Cirrhosis requiring active medical management.
  9. Malignancy requiring active treatment (except basal cell skin cancer).
  10. Subjects with documented active alcohol and /or other substance abuse.
  11. Females of child bearing potential unless a pregnancy test is negative within 7 days of the mini-bone marrow harvest.
  12. Re-occlusion of the IRA prior to the infusion procedure.
  13. Planned revascularization intervention during the next 6 months (A second PCI can be performed if done prior to qualifying CMR at least 96 hours post primary PCI).
  14. Participation in an ongoing investigational trial.
  15. Active or suspected bacterial infection requiring systemic intravenous antibiotics.
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Caladrius Biosciences, Inc.
Caladrius Biosciences, Inc.
Not Provided
Study Director: Tom Moss, MD Caladrius Biosciences, Inc.
Principal Investigator: Arshed Quyyumi, MD Emory University
Caladrius Biosciences, Inc.
April 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP